Healthcare [ 4/11 ] | Diagnostics & Research [ 98/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 23 | -0.40 Decreased by -29.03% | -0.44 Increased by +20.66% |
| Feb 23, 23 | -0.41 Decreased by -10.81% | -0.45 Increased by +19.75% |
| Nov 8, 22 | -0.30 Increased by +14.29% | -0.40 Increased by +62.50% |
| Aug 3, 22 | -0.31 Increased by +8.82% | -0.36 Increased by +38.58% |
| May 10, 22 | -0.31 Increased by +45.61% | -0.40 Increased by +56.25% |
| Feb 24, 22 | -0.37 Decreased by -23.33% | -0.36 Decreased by -7.72% |
| Nov 2, 21 | -0.35 Decreased by -40.00% | -0.28 Decreased by -89.29% |
| Aug 5, 21 | -0.34 Decreased by -21.43% | -0.28 Decreased by -76.53% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 2.53 M Increased by +73.98% | -26.40 M Decreased by -51.12% | Decreased by -1.04 K% Increased by +13.14% |
| Dec 31, 22 | 7.75 M Increased by +416.52% | -33.29 M Decreased by -45.99% | Decreased by -429.40% Increased by +71.74% |
| Sep 30, 22 | 19.02 M Increased by +1.05 K% | -21.23 M Decreased by -0.40% | Decreased by -111.63% Increased by +91.24% |
| Jun 30, 22 | 1.53 M Decreased by -16.23% | -16.67 M Increased by +8.21% | Decreased by -1.09 K% Decreased by -9.57% |
| Mar 31, 22 | 1.45 M Decreased by -18.23% | -17.47 M Increased by +39.24% | Decreased by -1.20 K% Increased by +25.69% |
| Dec 31, 21 | 1.50 M Decreased by -5.00% | -22.80 M Decreased by -73.11% | Decreased by -1.52 K% Decreased by -82.22% |
| Sep 30, 21 | 1.66 M Increased by +14.49% | -21.15 M Decreased by -98.39% | Decreased by -1.27 K% Decreased by -73.27% |
| Jun 30, 21 | 1.82 M Decreased by -10.85% | -18.16 M Decreased by -56.60% | Decreased by -995.67% Decreased by -75.66% |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.